I’ve written about this before,
but now there is some new information. Gaboxadol (THIP;
4,5,6,7-tetrahydroisoxazolo- [5,4-c] pyridin-3-ol)
is an investigational drug being developed by Lundbeck in
conjunction with Merck.
(image from ChemBank)
At the 2006 Associated Professional Sleep Societies Conference
in Salt Lake City, Utah, data
were presented from Phase II trials of the drug.
They report that the compound has advanced to Phase III
trials, with the intent of getting the drug approved for treatment of
Results Gaboxadol 20 mg and
zolpidem 10 mg significantly increased total sleep time (TST) with 53
minutes compared to baseline (P <.05 compared to placebo) and
gaboxadol 20 mg significantly reduced wakefulness after sleep onset
(WASO) with 27 minutes compared to baseline (P <.05 compared to
placebo). Both gaboxadol 10 and 20 mg but not zolpidem significantly
reduced number of awakenings by 9 compared to baseline (P >.001
compared to placebo). Neither drug significantly reduced sleep onset
latency. However, gaboxadol 20 mg improved self-reported “quality of
sleep” (P <.05).
Both gaboxadol doses enhanced slow wave sleep in a dose dependent
Tolerability and next-day residual effects Neither
drug treatment was associated with next day residual effects the
morning after treatment. The majority of adverse events (AE) were mild
or moderate with no serious AEs. Compared to placebo, the incidence and
severity of AEs were higher with gaboxadol 20 mg.
The improvement in slow wave sleep is of particular interest.
Few other drugs do that. Slow
wave sleep generally is considered to be the kind of sleep
that is most restorative. It is thought to be important for memory
consolidation. Deficit of slow-wave sleep is associated
Gaboxadol is a peculiar CNS drug: it acts at nonsynaptic
receptors. It has a selective effect on GABA-A
which is not terribly unusual these days, but the demonstration of
activity upon receptors that are not located at a
neuronal synapse is
have shown that the mechanism of action of gaboxadol is distinct from
that of benzodiazepines
(and ethanol). Although there are many drugs for insomnia on
the market, it won’t really be a “me too” drug. It is
classified as a selective extrasynaptic GABAA agonist,
giving rise to yet another acronym: SEGA.
Lundbeck and Merck expect to file for FDA approval in the USA in 2007.
(Non-disclaimer: I don’t own stock in any drug companies, at
least not directly.)